Our Legacy
A Journey of Growth, Innovation, & Impact
1997
company founded
Delta Pharma was established, marking the beginning of our journey in pharmaceutical manufacturing and healthcare innovation.
1999
Dolphin Suppository Launch
We introduced our first product, to the local market, laying the foundation for sustained growth. Today, Dolphin stands as the market leader in antipyretic suppositories in Egypt, reinforcing its long-term trust and value in the healthcare community.
2003
Technology Upgrade & Line Expansion
We expanded production capabilities by installing advanced technologies, including plastering, PAM filling, automatic inspection, and labeling systems.
2004
Gaptin Launch
Marking Delta Pharma’s first entry into the CNS therapeutic area and significantly expanding our product portfolio. Today, Gaptin proudly stands as the number one prescribed product in its category in Egypt, reinforcing its strong and consistent market leadership
2004
First Export
Initiated international expansion with exports to Sudan and Yemen, marking our early entry into African and regional markets.
2008
Acquisition by Al-Ritaj Group
Delta Pharma joined Al-Ritaj Holding, a strategic move that strengthened our resources, capabilities, and growth potential.
2014
Sterile Production Line Commissioned
We launched an advanced sterile production facility for vials, elevating our quality and safety standards.
2015
Expansion into Toll Manufacturing
Delta Pharma began offering toll manufacturing services, leveraging our high-capacity, GMP-compliant production lines to support other
2017
Production Milestone
Surpassed 70 million units in cumulative production, demonstrating our commitment to market demand and operational excellence.
2017
Equipment Upgrades
Upgraded coating machine to enhance efficiency and product finish.
2024
QC Labs Modernization
Upgraded and modernized Quality Control laboratories to strengthen analytical capabilities and ensure superior product standards.
2024
Export Growth
Expanded international footprint, exporting to over 13 countries, with a focus on Africa and the Middle East.
2026
Launching 8 new products
Delta Pharma expanded its portfolio with seven new products across multiple therapeutic areas:
Gastrointestinal: Ondeltatron ampoules and Nauseguard tablets
Cardiometabolic: Rosuvamib Tablet
Vitamins & Minerals: Deltavit Plus tablets and Regnavit tablets
Neuropsychiatry: Sinovortex tablets
Musculoskeletal: Flabu tablets & drops, and Menthor Gel
This expansion reinforces our commitment to addressing diverse patient needs across key therapy areas.